What Do Case Reports Tell Us About Ozempic and Gastroparesis?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Drug Safety Concerns

If you or someone you know has developed persistent nausea, vomiting, or abdominal pain after starting Ozempic, you may be wondering whether the medication could be a factor. The long-standing tradition of medical case reporting has helped identify rare adverse events that may not appear in initial trials. This page reviews published case histories and research updates on the potential link between Ozempic and gastroparesis.

Ozempic and Gastroparesis: The Medical Link

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant concern. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, abdominal pain, and bloating. Diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules, with symptoms correlating to the degree of delay. The mechanistic pathway linking Ozempic to gastroparesis is rooted in its GLP-1 receptor agonism, which inhibits gastric motility and antral contractions while relaxing the pyloric sphincter. This effect, intended to slow nutrient absorption, can become pathological in susceptible individuals, leading to sustained gastroparesis even after drug discontinuation in some cases. Evidence from clinical trials underscores the frequency of gastrointestinal adverse reactions associated with Ozempic. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients with type 2 diabetes mellitus included nausea (placebo 6.1%, Ozempic 0.5 mg 15.8%, Ozempic 1 mg 20.3%), vomiting (placebo 2.3%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 9.2%), diarrhea (placebo 1.9%, Ozempic 0.5 mg 8.5%, Ozempic 1 mg 8.8%), abdominal pain (placebo 4.6%, Ozempic 0.5 mg 7.3%, Ozempic 1 mg 5.7%), and constipation (placebo 1.5%, Ozempic 0.5 mg 5.0%, Ozempic 1 mg 3.1%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, gastrointestinal adverse reactions with a frequency of <5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Legal Considerations: Statute of Limitations for Ozempic Claims in Michigan

The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk anchor. The prescribing information for Ozempic lists gastrointestinal adverse reactions but does not explicitly warn of gastroparesis as a distinct adverse event. Instead, it describes symptoms such as nausea, vomiting, and abdominal pain, which overlap with gastroparesis presentation. This lack of specific warning may leave patients and healthcare providers unaware of the potential for a chronic motility disorder. For affected patients, attorney-related considerations include evaluating whether the manufacturer provided sufficient information about the risk of severe or persistent gastrointestinal dysfunction. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials, but may persist or worsen over time. Patients who develop gastroparesis after using Ozempic may face prolonged suffering, nutritional deficiencies, and reduced quality of life. In Michigan, the statute of limitations for product liability claims, including those related to pharmaceutical injuries, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis linked to Ozempic, this means patients must file a claim within three years of recognizing that their symptoms are attributable to the drug. Given the delayed onset and gradual progression of gastroparesis, careful documentation of symptom onset, diagnosis, and correlation with Ozempic use is essential. Patients should consult with an attorney experienced in pharmaceutical litigation to assess their case, as the statute of limitations can be complex and may vary based on specific circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in Michigan?

In Michigan, the statute of limitations for product liability claims, including those related to pharmaceutical injuries, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For gastroparesis linked to Ozempic, this means patients must file a claim within three years of recognizing that their symptoms are attributable to the drug. It is important to consult with an attorney to understand how this applies to your specific situation.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic lists gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, but does not explicitly warn of gastroparesis as a distinct adverse event. This lack of specific warning may leave patients and healthcare providers unaware of the potential for a chronic motility disorder. For more details, refer to the official prescribing information at DailyMed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.